Establishment Labs Holdings announced that it has surpassed 3 million Motiva devices in market. The devices have been delivered to plastic and reconstructive surgeons since 2010 and are available in more than 85 countries.
“Since its founding, Establishment Labs has been guided by one core principle: putting women at the center of everything we do,” Juan José Chacón-Quirós, Establishment Labs CEO and Founder, said in a company news release. “We let science, engineering, and evidence drive our research and development, and this is reflected in the outstanding performance of our portfolio of solutions for breast aesthetics and reconstruction. By leading with innovation for over 12 years now, we have transformed the future of this industry.”
“Our expectations for continued growth are clear: with our new Sulàyöm Campus, which is opening in July, we are more than doubling our manufacturing capacity to address the growing demand for Motiva,” said Dr. Heather Brennan, General Manager, Global Markets. “We believe that by setting new standards in safety and clinical performance, we will expand markets in breast aesthetics and reconstruction.”
Establishment Labs’ 2022 Post Market Surveillance Report is available at: Motiva PMS Report. Motiva Implants are undergoing an IDE clinical trial and are not approved for sale in the United States.
